Resistance to Fas-Mediated Apoptosis Does Not Correlate to Structural Alterations or Expression Changes of the Death Receptor in Papillary Thyroid Carcinomas

被引:1
作者
Fanourakis, Galinos [1 ]
Saetta, Angelica A. [1 ]
Lazaris, Andreas C. [1 ]
Miaouli, Maria [1 ]
Voutsinas, Gerassimos E. [2 ]
Patsouris, Efstratios [1 ]
Tseleni-Balafouta, Sofia [1 ]
机构
[1] Univ Athens, Sch Med, Dept Pathol 1, 75 Mikras Asias St, GR-11527 Athens, Greece
[2] Natl Ctr Sci Res NCSR Demokritos, Inst Biosci & Applicat, Lab Environm Mutagenesis & Carcinogenesis, Athens, Greece
关键词
FAS receptor; Apoptosis; P53; Mutations; Immunohistochemistry; Reverse-transcription polymerase chain reaction; Thyroid cancer; APO-1/CD95; GENE; P53; MUTATIONS; CANCER; LIGAND; DOMAIN;
D O I
10.1159/000492358
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: Malignant cells exhibit significant resistance to FAS-mediated cell death, through different processes, including FAS mutations, soluble FAS expression, or FAS transcriptional dysregulation by P53, eventually escaping from immune surveillance. Since thyroid carcinomas were shown to be resistant to FAS-mediated apoptosis, we investigated the above mechanisms in thyroid carcinoma samples. Methods: Thirty-seven thyroid carcinoma samples were analyzed for mutations in FAS exon 9 and TP53 exons 5-8 and protein expression by means of immunohistochemistry. Moreover, thyroid carcinoma mRNA samples were subjected to reverse transcription - PCR, to evaluate the relative expression of transmembrane FAS versus its soluble form. Results: Analysis revealed indications for TP53 mutations in the anaplastic carcinomas, but not in the other thyroid specimens examined for TP53 or FAS exon 9 mutations. FAS receptor expression was observed in almost all thyroid specimens (97%) with significant up-regulation in papillary carcinomas. P53 nuclear staining was observed only in anaplastic carcinomas. Full-length FAS mRNA was detected in all specimens examined, with soluble FAS mRNA being either absent or present in very low amounts. Conclusions: Our results denote that FAS death domain or TP53 DNA-binding domain mutations, down-regulation of FAS receptor expression, or expression of FAS soluble isoform are not responsible for the seeming inhibition of FAS-mediated apoptosis in papillary thyroid carcinoma cells.
引用
收藏
页码:304 / 310
页数:7
相关论文
共 38 条
  • [1] Integrated Genomic Characterization of Papillary Thyroid Carcinoma
    Agrawal, Nishant
    Akbani, Rehan
    Aksoy, B. Arman
    Ally, Adrian
    Arachchi, Harindra
    Asa, Sylvia L.
    Auman, J. Todd
    Balasundaram, Miruna
    Balu, Saianand
    Baylin, Stephen B.
    Behera, Madhusmita
    Bernard, Brady
    Beroukhim, Rameen
    Bishop, Justin A.
    Black, Aaron D.
    Bodenheimer, Tom
    Boice, Lori
    Bootwalla, Moiz S.
    Bowen, Jay
    Bowlby, Reanne
    Bristow, Christopher A.
    Brookens, Robin
    Brooks, Denise
    Bryant, Robert
    Buda, Elizabeth
    Butterfield, Yaron S. N.
    Carling, Tobias
    Carlsen, Rebecca
    Carter, Scott L.
    Carty, Sally E.
    Chan, Timothy A.
    Chen, Amy Y.
    Cherniack, Andrew D.
    Cheung, Dorothy
    Chin, Lynda
    Cho, Juok
    Chu, Andy
    Chuah, Eric
    Cibulskis, Kristian
    Ciriello, Giovanni
    Clarke, Amanda
    Clayman, Gary L.
    Cope, Leslie
    Copland, John A.
    Covington, Kyle
    Danilova, Ludmila
    Davidsen, Tanja
    Demchok, John A.
    DiCara, Daniel
    Dhalla, Noreen
    [J]. CELL, 2014, 159 (03) : 676 - 690
  • [2] [Anonymous], 1996, FRONT BIOSCI
  • [3] Fas (CD95) expression is up-regulated on papillary thyroid carcinoma
    Arscott, PL
    Stokes, T
    Myc, A
    Giordano, TJ
    Thompson, NW
    Baker, JR
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (11) : 4246 - 4252
  • [4] Wig-1 regulates cell cycle arrest and cell death through the p53 targets FAS and 14-3-3σ
    Bersani, C.
    Xu, L-D
    Vilborg, A.
    Lui, W-O
    Wiman, K. G.
    [J]. ONCOGENE, 2014, 33 (35) : 4407 - 4417
  • [5] CASCINO I, 1995, J IMMUNOL, V154, P2706
  • [6] The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
    Cerami, Ethan
    Gao, Jianjiong
    Dogrusoz, Ugur
    Gross, Benjamin E.
    Sumer, Selcuk Onur
    Aksoy, Buelent Arman
    Jacobsen, Anders
    Byrne, Caitlin J.
    Heuer, Michael L.
    Larsson, Erik
    Antipin, Yevgeniy
    Reva, Boris
    Goldberg, Arthur P.
    Sander, Chris
    Schultz, Nikolaus
    [J]. CANCER DISCOVERY, 2012, 2 (05) : 401 - 404
  • [7] Up-regulation of Fas ligand and down-regulation of Fas expression in oral carcinogenesis
    Chen, QM
    Samaranayake, LP
    Zhen, X
    Luo, G
    Nie, MH
    Li, BQ
    [J]. ORAL ONCOLOGY, 1999, 35 (06) : 548 - 553
  • [8] PROTECTION FROM FAS-MEDIATED APOPTOSIS BY A SOLUBLE FORM OF THE FAS MOLECULE
    CHENG, JH
    ZHOU, T
    LIU, CD
    SHAPIRO, JP
    BRAUER, MJ
    KIEFER, MC
    BARR, PJ
    MOUNTZ, JD
    [J]. SCIENCE, 1994, 263 (5154) : 1759 - 1762
  • [9] STEPWISE PARTICIPATION OF P53 GENE MUTATION DURING DEDIFFERENTIATION OF HUMAN THYROID CARCINOMAS
    DOBASHI, Y
    SUGIMURA, H
    SAKAMOTO, A
    MERNYEI, M
    MORI, M
    OYAMA, T
    MACHINAMI, R
    [J]. DIAGNOSTIC MOLECULAR PATHOLOGY, 1994, 3 (01) : 9 - 14
  • [10] GENE P53 MUTATIONS ARE RESTRICTED TO POORLY DIFFERENTIATED AND UNDIFFERENTIATED CARCINOMAS OF THE THYROID-GLAND
    DONGHI, R
    LONGONI, A
    PILOTTI, S
    MICHIELI, P
    DELLAPORTA, G
    PIEROTTI, MA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (04) : 1753 - 1760